The Department of Defense is offering the Tuberous Sclerosis Complex Idea Development Award to support innovative and high-impact research projects in the early stages of development. This grant focuses on promoting new ideas that could lead to critical discoveries in TSC research or advancements in patient care. Applicants must provide well-formulated, testable hypotheses with strong scientific rationale, along with unpublished or relevant preliminary data. Projects should adhere to rigorous study design standards and consider the impact of the proposed research on both short and long-term TSC research and patient care. The closing date for applications is July 27, 2015.
Opportunity ID: 276403
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-TSCRP-IDA |
| Funding Opportunity Title: | DoD Tuberous Sclerosis Complex Idea Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 06, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 27, 2015 |
| Current Closing Date for Applications: | Jul 27, 2015 |
| Archive Date: | Aug 26, 2015 |
| Estimated Total Program Funding: | $3,360,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The IDA promotes new ideas that are in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. The following are important aspects of the Idea Development Award: 1. Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative. 2. Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. 3. Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, should be included. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (http://www.nature.com/nature/journal/ v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment X, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.elsevier.com/__data/promis_misc/ 622936arrive_guidelines.pdf. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 276403 Full Announcement-1 -> tscrp_fy15_ida_pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00216704 | May 06, 2015 | Jul 27, 2015 | View |
Package 1
Mandatory forms
276403 RR_SF424_2_0-2.0.pdf
276403 RR_Budget_1_3-1.3.pdf
276403 RR_KeyPersonExpanded_2_0-2.0.pdf
276403 PerformanceSite_2_0-2.0.pdf
Optional forms
276403 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
